logo

Lyra Therapeutics, Inc. (LYRA)



Trade LYRA now with
  Date
  Headline
5/10/2022 7:30:27 AM Lyra Therapeutics Q1 Net Loss $7.0 Mln Vs. Loss $7.8 Mln Prior Year
4/29/2022 9:08:50 AM Lyra Presents Positive Data From LANTERN Phase 2 Study Of LYR-210 For Treatment Of Chronic Rhinosinusitis
4/25/2022 7:20:54 AM Lyra Therapeutics Announces First Patient Treated In Phase 2 BEACON Clinical Trial Of LYR-220
3/9/2022 7:14:05 AM Lyra Therapeutics Q4 Net Loss $13.6 Mln Vs. Loss $7 Mln Prior Year
2/28/2022 7:02:58 AM Lyra Therapeutics Says First Patient Dosed In ENLIGHTEN I Trial Of LYR-210 In Chronic Rhinosinusitis Patients
2/17/2022 7:04:40 AM Lyra Therapeutics Names Harlan Waksal Executive Chairman
10/4/2021 7:09:04 AM Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up And LYR-210 Pharmacokinetic Data
9/13/2021 7:11:35 AM Lyra Therapeutics Appoints Jason Cavalier As CFO
6/30/2021 7:15:39 AM Lyra Therapeutics Announces Positive Topline Results Of Pharmacokinetic Study Of LYR-210 In Chronic Rhinosinusitis
6/2/2021 7:31:27 AM Lyra, LianBio Announce Strategic Partnership And License Deal To Develop LYR-210 In Greater China And Asian Markets
2/17/2021 8:25:21 AM Lyra Therapeutics Names Robert Kern Chief Medical Officer
1/22/2021 8:09:53 AM Lyra To Initiate Phase 2 Trial For LYR-220 And To Explore Further Opportunities